Intec Pharma (NTEC) IPO Opens Flat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
Intec Pharma Ltd. Announces Pricing of U.S. Initial Public Offering
August 4, 2015 9:25 AM EDTJERUSALEM, Aug. 4, 2015 /PRNewswire/ -- Intec Pharma Ltd. (the "Company") (NASDAQ: NTEC), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, today announced the pricing of its initial public offering in the United States of 5,025,000 of its ordinary shares at a price to the public of $6.00 per ordinary share, before underwriting discounts and commissions. All of the ordinary shares are being offered by the Company. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 753,750 ordinary... More
